Use of In-111 Capromab Pendetide in detecting metastatic prostate cancer

Howell T, Hailey D
Record ID 31998009926
Authors' objectives: To summarise the effectiveness and cost-effectiveness of In-111 Capromab Pendetide in detecting metastatic prostate cancer.
Authors' recommendations: Imaging with In-111 Capromab Pendetide provides an additional method for detection of metastatic disease in prostate cancer. As the images are difficult to interpret, it would be essential for clinicians to receive appropriate training. Studies of the diagnostic accuracy of In-111 Capromab Pendetide have achieved moderate results with sensitivity ranging between 44 and 89% and specificity ranging between 67 and 86%. Indications are that the appropriate role for In-111 Capromab Pendetide is as an adjunct to other diagnostic approaches. There are no studies which report on its effect on clinical decisions or patient outcomes. Use of In-111 Capromab Pendetide may be indicated in a small number of selected patients.
Authors' methods: Systematic review
Project Status: Completed
Year Published: 1999
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Diagnostic Imaging
  • Prostatic Neoplasms
Organisation Name: Institute of Health Economics
Contact Address: 1200, 10405 Jasper Avenue, Edmonton, Alberta, Canada, T5J 3N4. Tel: +1 780 448 4881; Fax: +1 780 448 0018;
Contact Name:
Contact Email:
Copyright: Alberta Heritage Foundation for Medical Research
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.